Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets

Archives of Toxicology

Volumn 89, Issue 9, 2015, Pages 1401-1438

  Tham, Yow Keat ^a,b   Bernardo, Bianca C ^a   Ooi, Jenny Y Y ^a   Weeks, Kate L ^c   McMullen, Julie R ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Heart failure; Maladaptive heart growth; Pathological hypertrophy; Signaling cascades; Therapeutic applications

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CCAAT ENHANCER BINDING PROTEIN BETA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN GP 130; HEAT SHOCK PROTEIN; HEAT SHOCK TRANSCRIPTION FACTOR 1; HEXAMETHYLENE BIS ACETAMIDE INDUCIBLE PROTEIN 1; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; JANUS KINASE; MICRORNA; MINERALOCORTICOID ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE; PRAS40 PROTEIN; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN PHOSPHATASE PHLPP1; SOMATOMEDIN C; STAT PROTEIN; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CELL DEATH; DIET SUPPLEMENTATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART DEVELOPMENT; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE CELL; CARDIOMEGALY; HEART VENTRICLE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOMEGALY; HEART FAILURE; HEART VENTRICLES; HUMANS; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION;

EID: 84940586899     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-015-1477-x     Document Type: Review

References (472)

1. Abdel-Latif A, Bolli R, Tleyjeh IM et al (2007) Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167(10):989–997
2. Abozguia K, Elliott P, McKenna W et al (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122(16):1562–1569
3. Aiello LP, Vignati L, Sheetz MJ et al (2011) Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina 31(10):2084–2094
4. AIRE_Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342(8875):821–828
5. Aker S, Belosjorow S, Konietzka I et al (2003) Serum but not myocardial TNF-α concentration is increased in pacing-induced heart failure in rabbits. Am J Physiol Regul Integr Comp Physiol 285(2):R463–R469
6. Akki A, Smith K, Seymour AM (2008) Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem 311(1–2):215–224
7. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD (1994) Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 267(2 Pt 2):H742–H750
8. Al-Shudiefat AA, Sharma AK, Bagchi AK, Dhingra S, Singal PK (2013) Oleic acid mitigates TNF-alpha-induced oxidative stress in rat cardiomyocytes. Mol Cell Biochem 372(1–2):75–82
9. Anand I, Chandrashekhan Y, De Giuli F et al (1998) Acute and chronic effects of propionyl-l-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 12(3):291–299
10. Anderson ME, Brown JH, Bers DM (2011) CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 51(4):468–473
11. Anderson ME, Goldhaber J, Houser SR, Puceat M, Sussman MA (2014) Embryonic stem cell-derived cardiac myocytes are not ready for human trials. Circ Res 115(3):335–338
12. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M (1993) Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72(2):463–469
13. Arsanjani R, McCarren M, Bahl JJ, Goldman S (2011) Translational potential of thyroid hormone and its analogs. J Mol Cell Cardiol 51(4):506–511
14. Ashrafian H, Horowitz JD, Frenneaux MP (2007) Perhexiline. Cardiovasc Drug Rev 25(1):76–97
15. Asokan A, Schaffer DV, Samulski RJ (2012) The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 20(4):699–708
16. Ather S, Respress JL, Li N (1832) Wehrens XHT (2013) Alterations in ryanodine receptors and related proteins in heart failure. Biochim Biophys Acta (BBA) Mol Basis Dis 12:2425–2431
17. Augoustides JG, Riha H (2009) Recent progress in heart failure treatment and heart transplantation. J Cardiothorac Vasc Anesth 23(5):738–748
18. Aukrust P, Ueland T, Lien E et al (1999) Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83(3):376–382
19. Backs J, Worst BC, Lehmann LH et al (2011) Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol 195(3):403–415
20. Bader AG (2012) miR-34—a microRNA replacement therapy is headed to the clinic. Front Genet 3:120
21. Ballou LM, Lin RZ, Cohen IS (2015) Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels. Circ Res 116(1):127–137
22. Bang HO, Dyerberg J, Hjoorne N (1976) The composition of food consumed by Greenland Eskimos. Acta Med Scand 200(1–2):69–73
23. Banke NH, Wende AR, Leone TC et al (2010) Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ Res 107(2):233–241
24. Banquet S, Gomez E, Nicol L et al (2011) Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 124(9):1059–1069
25. Batista PJ, Chang HY (2013) Long noncoding RNAs: cellular address codes in development and disease. Cell 152(6):1298–1307
26. Baum J, Duffy HS (2011) Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol 57(4):376–379
27. Baumgarten G, Knuefermann P, Kalra D et al (2002) Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation 105(18):2192–2197
28. Bedotto JB, Gay RG, Graham SD, Morkin E, Goldman S (1989) Cardiac hypertrophy induced by thyroid hormone is independent of loading conditions and beta adrenoceptor blockade. J Pharmacol Exp Ther 248(2):632–636
29. Belakavadi M, Saunders J, Weisleder N, Raghava PS, Fondell JD (2010) Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-{alpha}1 and involves targeted covalent histone modifications. Endocrinology 151(6):2946–2956
30. Belin RJ, Greenland P, Martin L et al (2011) Fish intake and the risk of incident heart failure: the Women’s Health Initiative. Circ Heart Fail 4(4):404–413
31. Benito M, Oria R, Sanchez-Gimeno AC (2010) Characterization of the olive oil from three potentially interesting varieties from Aragon (Spain). Food Sci Technol Int 16(6):523–530
32. Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 128(1):191–227
33. Bernardo BC, Charchar FJ, Lin RCY, McMullen JR (2012a) A MicroRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ 21(3):131–142
34. Bernardo BC, Gao XM, Winbanks CE et al (2012b) Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci USA 109(43):17615–17620
35. Bernardo BC, Gao XM, Tham YK et al (2014a) Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy. PLoS ONE 9(2):e90337
36. Bernardo BC, Nguyen SS, Winbanks CE et al (2014b) Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J 28(12):5097–5110
37. Bers DM (2006) Altered cardiac myocyte Ca regulation in heart failure. Am Physiol Soc 21:380–387
38. Bers DM (2014) Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction. Annu Rev Physiol 76:107–127
39. Bharadwaj KG, Hiyama Y, Hu Y et al (2010) Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. J Biol Chem 285(49):37976–37986
40. Bhuiyan MS, Pattison JS, Osinska H et al (2013) Enhanced autophagy ameliorates cardiac proteinopathy. J Clin Invest 123(12):5284–5297
41. Bienvenu LA, Reichelt ME, Delbridge LM, Young MJ (2013) Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte. Clin Sci 125(9):409–421
42. Bish LT, Morine K, Sleeper MM et al (2008) Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 19(12):1359–1368
43. Bolli R, Chugh AR, D’Amario D et al (2011) Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378(9806):1847–1857
44. Boon RA, Iekushi K, Lechner S et al (2013) MicroRNA-34a regulates cardiac ageing and function. Nature 495(7439):107–110
45. Bossuyt J, Chang CW, Helmstadter K et al (2011) Spatiotemporally distinct protein kinase D activation in adult cardiomyocytes in response to phenylephrine and endothelin. J Biol Chem 286(38):33390–33400
46. Boström P, Mann N, Wu J et al (2010) C/EBP beta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143(7):1072–1083
47. 2+-sensitive isoforms in the failing human heart. Circulation 99(3):384–391
48. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM (1997) Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 100(9):2189–2195
49. Bradner JE, West N, Grachan ML et al (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6(3):238–243
50. Braunwald E (2014) The war against heart failure: the Lancet lecture. Lancet. doi:10.1016/S0140-6736(14)61889-4
51. Braz JC, Bueno OF, De Windt LJ, Molkentin JD (2002) PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). J Cell Biol 156(5):905–919
52. Braz JC, Gregory K, Pathak A et al (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10(3):248–254
53. Brinks H, Boucher M, Gao E et al (2010) Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res 107(9):1140–1149
54. Bristow MR (2000) beta-adrenergic receptor blockade in chronic heart failure. Circulation 101(5):558–569
55. Broderick TL, Quinney HA, Barker CC, Lopaschuk GD (1993) Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 87(3):972–981
56. Bueno OF, De Windt LJ, Tymitz KM et al (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19(23):6341–6350
57. Bueno OF, van Rooij E, Molkentin JD, Doevendans PA, De Windt LJ (2002) Calcineurin and hypertrophic heart disease: novel insights and remaining questions. Cardiovasc Res 53(4):806–821
58. Burr ML, Fehily AM, Gilbert JF et al (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2(8666):757–761
59. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM (2008) Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 15(23):1550–1557
60. Cabili MN, Trapnell C, Goff L et al (2011) Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 25(18):1915–1927
61. Calvani M, Reda E, Arrigoni-Martelli E (2000) Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol 95(2):75–83
62. Cannavo A, Liccardo D, Koch WJ (2013) Targeting cardiac beta-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front Physiol 4:264
63. Cardinale JP, Sriramula S, Pariaut R et al (2010) HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 56(3):437–444
64. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR (2004) Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279(31):32771–32779
65. Chan AY, Dolinsky VW, Soltys CL et al (2008) Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 283(35):24194–24201
66. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24(19):8467–8476
67. Chau VQ, Salloum FN, Hoke NN, Abbate A, Kukreja RC (2011) Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol 300(6):H2272–H2279
68. Chen L, Hahn H, Wu G et al (2001) Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci USA 98(20):11114–11119
69. Chen J-F, Murchison EP, Tang R et al (2008) Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 105(6):2111–2116
70. Chen J, Shearer GC, Chen Q et al (2011) Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 123(6):584–593
71. Chien KR, Zangi L, Lui KO (2014) Synthetic Chemically Modified mRNA (modRNA): Toward a New Technology Platform for Cardiovascular Biology and Medicine. Cold Spring Harb Perspect Med 5(1). doi:10.1101/cshperspect.a014035
72. Chong JJH, Yang X, Don CW et al (2014) Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510(7504):273–277
73. Choudhary C, Kumar C, Gnad F et al (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942):834–840
74. Chung J, Nguyen AK, Henstridge DC et al (2008) HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci USA 105(5):1739–1744
75. CIBIS-II Investigators (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353(9146):9–13
76. Cittadini A, Monti MG, Iaccarino G et al (2012) SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. Cardiovasc Res 96(3):381–390
77. Connelly KA, Kelly DJ, Zhang Y et al (2009) Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2(2):129–137
78. CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316(23):1429–1435
79. Crackower MA, Oudit GY, Kozieradzki I et al (2002) Regulation of myocardial contractility and cell size by distinct PI3K–PTEN signaling pathways. Cell 110(6):737–749
80. Creemers EE, Tijsen AJ, Pinto YM (2012) Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 110(3):483–495
81. Crossman DJ, Ruygrok PN, Soeller C, Cannell MB (2011) Changes in the organization of excitation–contraction coupling structures in failing human heart. PLoS ONE 6(3):e17901
82. da Costa Martins PA, Bourajjaj M, Gladka M et al (2008) Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 118(15):1567–1576
83. Da Silva ND Jr, Fernandes T, Soci UP, Monteiro AW, Phillips MI, de Oliveira EM (2012) Swimming training in rats increases cardiac MicroRNA-126 expression and angiogenesis. Med Sci Sports Exerc 44(8):1453–1462
84. Dai DF, Johnson SC, Villarin JJ et al (2011) Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res 108(7):837–846
85. Daige CL, Wiggins JF, Priddy L, Nelligan-Davis T, Zhao J, Brown D (2014) Systemic delivery of a miR-34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther 13(10):2352–2360
86. D’Angelo DD, Sakata Y, Lorenz JN et al (1997) Transgenic Galpha q overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 94(15):8121–8126
87. De Maeyer C, Beckers P, Vrints CJ, Conraads VM (2013) Exercise training in chronic heart failure. Ther Adv Chron Dis 4(3):105–117
88. De Maio A (1999) Heat shock proteins: facts, thoughts, and dreams. Shock 11(1):1–12
89. DeBosch B, Treskov I, Lupu TS et al (2006) Akt1 is required for physiological cardiac growth. Circulation 113(17):2097–2104
90. Demarquoy J, Georges B, Rigault C et al (2004) Radioisotopic determination of l-carnitine content in foods commonly eaten in Western countries. Food Chem 86(1):137–142
91. Den Ruijter HM, Verkerk AO, Schumacher CA et al (2012) A diet rich in unsaturated fatty acids prevents progression toward heart failure in a rabbit model of pressure and volume overload. Circ Heart Fail 5(3):376–384
92. Dhalla NS, Müller AL (2010) Protein kinases as drug development targets for heart disease therapy. Pharmaceuticals 3:2111–2145
93. Dijkstra SC, Brouwer IA, van Rooij FJ, Hofman A, Witteman JC, Geleijnse JM (2009) Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. Eur J Heart Fail 11(10):922–928
94. Diwan A, Dorn GW 2nd (2007) Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology 22:56–64
95. Dobrev D, Wehrens XH (2014) Role of RyR2 phosphorylation in heart failure and arrhythmias: controversies around ryanodine receptor phosphorylation in cardiac disease. Circ Res 114(8):1311–1319 (discussion 1319)
96. Dorn GW II, Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527–537
97. Dorn GW 2nd, Kitsis RN (2015) The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble. Circ Res 116(1):167–182
98. Du XJ (2008) Distinct role of adrenoceptor subtypes in cardiac adaptation to chronic pressure overload. Clin Exp Pharmacol Physiol 35(3):355–360
99. el Alaoui-Talibi Z, Landormy S, Loireau A, Moravec J (1992) Fatty acid oxidation and mechanical performance of volume-overloaded rat hearts. Am J Physiol 262(4 Pt 2):H1068–H1074
100. Engelhardt S, Hein L, Wiesmann F, Lohse MJ (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96(12):7059–7064
101. Estruch R, Ros E, Salas-Salvado J et al (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368(14):1279–1290
102. Eurich DT, Weir DL, Majumdar SR et al (2013) Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6(3):395–402
103. Fan GC, Chu G, Mitton B, Song Q, Yuan Q, Kranias EG (2004) Small heat-shock protein Hsp20 phosphorylation inhibits beta-agonist-induced cardiac apoptosis. Circ Res 94(11):1474–1482
104. Fan GC, Chu G, Kranias EG (2005) Hsp20 and its cardioprotection. Trends Cardiovasc Med 15(4):138–141
105. Fan GC, Yuan Q, Song G et al (2006) Small heat-shock protein Hsp20 attenuates beta-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1. Circ Res 99(11):1233–1242
106. Feldman MD, Copelas L, Gwathmey JK et al (1987) Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75(2):331–339
107. Finkle J, Bloomfield D, Uhl K, Sanhai W, Stockbridge N, Krucoff MW (2009) New precompetitive paradigms: focus on cardiac safety. Am Heart J 157(5):825–826
108. Finnin MS, Donigian JR, Cohen A et al (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401(6749):188–193
109. Fischer S, Glas KE (2013) A review of cardiac transplantation. Anesthesiol Clin 31(2):383–403
110. Fischer R, Dechend R, Qadri F et al (2008) Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 51(2):540–546
111. Fischle W, Dequiedt F, Hendzel MJ et al (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 9(1):45–57
112. Fish KM, Ladage D, Kawase Y et al (2013) AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Circ Heart Fail 6(2):310–317
113. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B (2014) Metformin: from mechanisms of action to therapies. Cell Metab 20(6):953–966
114. Friehs I, del Nido PJ (2003) Increased susceptibility of hypertrophied hearts to ischemic injury. Ann Thorac Surg 75(2):S678–S684
115. Friehs I, Margossian RE, Moran AM, Cao-Danh H, Moses MA, del Nido PJ (2006) Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol 101(3):204–213
116. Frishman WH (2003) Beta-adrenergic blockers. Circulation 107(18):e117–e119
117. Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13(2):140–156
118. Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9(6):447–464
119. Ganesan J, Ramanujam D, Sassi Y et al (2013) MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127(21):2097–2106
120. Gehrig SM, van der Poel C, Sayer TA et al (2012) Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature 484(7394):394–398
121. Ghose Roy S, Mishra S, Ghosh G, Bandyopadhyay A (2007) Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1. Matrix Biol 26(4):269–279
122. Giannetta E, Isidori AM, Galea N et al (2012) Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125(19):2323–2333
123. Giannetta E, Feola T, Gianfrilli D et al (2014) Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med 12(1):185
124. Gidlof O, Smith JG, Miyazu K et al (2013) Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc Disord 13:12
125. Giordano FJ (2005) Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115(3):500–508
126. GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 354(9177):447–455
127. Gonzalez GE, Rhaleb NE, D’Ambrosio MA et al (2015) Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J Hypertens 33(1):144–152
128. Gray MO, Zhou HZ, Schafhalter-Zoppoth I, Zhu P, Mochly-Rosen D, Messing RO (2004) Preservation of base-line hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C epsilon. J Biol Chem 279(5):3596–3604
129. Greenberg B, Yaroshinsky A, Zsebo KM et al (2014) Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart failure 2(1):84–92
130. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338(1):17–31
131. Gregorevic P, Blankinship MJ, Allen JM et al (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10(8):828–834
132. Grossman W, Jones D, McLaurin LP (1975) Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56(1):56–64
133. Grozinger CM, Schreiber SL (2000) Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA 97(14):7835–7840
134. Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4(1):8–17
135. Gundewar S, Calvert JW, Jha S et al (2009) Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 104(3):403–411
136. Guo D, Kassiri Z, Basu R et al (2010) Loss of PI3Kgamma enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res 107(10):1275–1289
137. Gwathmey JK, Copelas L, MacKinnon R et al (1987) Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61(1):70–76
138. Hahn HS, Marreez Y, Odley A et al (2003) Protein kinase Calpha negatively regulates systolic and diastolic function in pathological hypertrophy. Circ Res 93(11):1111–1119
139. Hajjar RJ, Zsebo K, Deckelbaum L et al (2008) Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 14(5):355–367
140. Hamilton KL, Staib JL, Phillips T, Hess A, Lennon SL, Powers SK (2003) Exercise, antioxidants, and HSP72: protection against myocardial ischemia/reperfusion. Free Radic Biol Med 34(7):800–809
141. Han P, Li W, Lin CH et al (2014) A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514(7520):102–106
142. Hang CT, Yang J, Han P et al (2010) Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 466(7302):62–67
143. Haq S, Choukroun G, Lim H et al (2001) Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103(5):670–677
144. Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13(4):251–262
145. Harrison BC, Roberts CR, Hood DB et al (2004) The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol 24(24):10636–10649
146. Hasenfuss G (1998) Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 37(2):279–289
147. Hasenfuss G, Reinecke H, Studer R et al (1994) Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res 75(3):434–442
148. Haubner BJ, Neely GG, Voelkl JG et al (2010) PI3Kgamma protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway. PLoS ONE 5(2):e9350
149. Hayakawa Y, Chandra M, Miao W et al (2003) Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation 108(24):3036–3041
150. Hein S, Arnon E, Kostin S et al (2003) Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107(7):984–991
151. Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM (2009) Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail 2(3):243–252
152. Higashikuni Y, Tanaka K, Kato M et al (2013) Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1beta upregulation via nuclear factor kappaB activation. J Am Heart Assoc 2(6):e000267
153. Hirota H, Chen J, Betz UA et al (1999) Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97(2):189–198
154. Hohl M, Wagner M, Reil JC et al (2013) HDAC4 controls histone methylation in response to elevated cardiac load. J Clin Invest 123(3):1359–1370
155. Hoshijima M, Ikeda Y, Iwanaga Y et al (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8(8):864–871
156. Houser SR (2014) Role of RyR2 phosphorylation in heart failure and arrhythmias: protein kinase A-mediated hyperphosphorylation of the ryanodine receptor at serine 2808 does not alter cardiac contractility or cause heart failure and arrhythmias. Circ Res 114(8):1320–1327 (discussion 1327)
157. Huang X, Fan R, Lu Y et al (2014) Regulatory effect of AMP-activated protein kinase on pulmonary hypertension induced by chronic hypoxia in rats: in vivo and in vitro studies. Mol Biol Rep 41(6):4031–4041
158. Hudlicka O, Brown MD (1996) Postnatal growth of the heart and its blood vessels. J Vasc Res 33(4):266–287
159. Hudson JE, Porrello ER (2013) The non-coding road towards cardiac regeneration. J Cardiovasc Transl Res 6(6):909–923
160. Hue L, Taegtmeyer H (2009) The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab 297(3):E578–E591
161. Huusko J, Lottonen L, Merentie M et al (2012) AAV9-mediated VEGF-B gene transfer improves systolic function in progressive left ventricular hypertrophy. Mol Ther 20(12):2212–2221
162. Huynh K, Bernardo BC, McMullen JR, Ritchie RH (2014) Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 142(3):375–415
163. Ibrahim M, Gorelik J, Yacoub MH, Terracciano CM (2011) The structure and function of cardiac t-tubules in health and disease. Proc Biol Sci 278(1719):2714–2723
164. Iemitsu M, Miyauchi T, Maeda S et al (2001) Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am J Physiol Regul Integr Comp Physiol 281(6):R2029–R2036
165. Ishikawa K, Fish KM, Tilemann L et al (2014) Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Mol Ther 22(12):2038–2045
166. Ishiwata T, Orosz A, Wang X et al (2012) HSPB2 is dispensable for the cardiac hypertrophic response but reduces mitochondrial energetics following pressure overload in mice. PLoS ONE 7(8):e42118
167. Iyer A, Fenning A, Lim J et al (2010) Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 159(7):1408–1417
168. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K (2006) Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47(5):887–893
169. Janssen HL, Reesink HW, Lawitz EJ et al (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368(18):1685–1694
170. Janssen R, Zuidwijk MJ, Kuster DW, Muller A, Simonides WS (2014) Thyroid hormone-regulated cardiac microRNAs are predicted to suppress pathological hypertrophic signaling. Front Endocrinol 5:171
171. Jarvinen R, Knekt P, Rissanen H, Reunanen A (2006) Intake of fish and long-chain n-3 fatty acids and the risk of coronary heart mortality in men and women. Br J Nutr 95(4):824–829
172. Jaski BE, Jessup ML, Mancini DM et al (2009) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 15(3):171–181
173. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, Malloy CR (1995) Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 25(3):469–472
174. 2+-ATPase in patients with advanced heart failure. Circulation 124(3):304–313
175. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N (2009) Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 55(11):1944–1949
176. Jiang DS, Wei X, Zhang XF et al (2014) IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nat Commun 5:3303
177. Kagawa Y, Nishizawa M, Suzuki M et al (1982) Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. J Nutr Sci Vitaminol 28(4):441–453
178. Karch R, Neumann F, Ullrich R et al (2005) The spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory cardiomyopathy. Cardiovasc Pathol 14(3):135–144
179. Kasinski AL, Kelnar K, Stahlhut C et al (2014) A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. doi:10.1038/onc.2014.282
180. Kawase Y, Ly HQ, Prunier F et al (2008) Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51(11):1112–1119
181. Kaye DM, Preovolos A, Marshall T et al (2007) Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 50(3):253–260
182. Kee HJ, Sohn IS, Nam KI et al (2006) Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113(1):51–59
183. Kee HJ, Bae EH, Park S et al (2013) HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity. Kidney Blood Press Res 37(4–5):229–239
184. Kehat I, Davis J, Tiburcy M et al (2011) Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 108(2):176–183
185. Keith M, Geranmayegan A, Sole MJ et al (1998) Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31(6):1352–1356
186. Kenessey A, Ojamaa K (2006) Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 281(30):20666–20672
187. Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118(1):10–24
188. Kho C, Lee A, Jeong D et al (2011) SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477(7366):601–605
189. Kienesberger PC, Pulinilkunnil T, Nagendran J, Dyck JR (2013) Myocardial triacylglycerol metabolism. J Mol Cell Cardiol 55:101–110
190. Kim TT, Dyck JR (2015) Is AMPK the savior of the failing heart? Trends Endocrinol Metab 26(1):40–48
191. Kim YK, Suarez J, Hu Y et al (2006) Deletion of the inducible 70-kDa heat shock protein genes in mice impairs cardiac contractile function and calcium handling associated with hypertrophy. Circulation 113(22):2589–2597
192. Kim J, Wende AR, Sena S et al (2008) Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endocrinol 22(11):2531–2543
193. Kim M, Shen M, Ngoy S, Karamanlidis G, Liao R, Tian R (2012) AMPK isoform expression in the normal and failing hearts. J Mol Cell Cardiol 52(5):1066–1073
194. Kiriazis H, Wang K, Xu Q et al (2008) Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis. Br J Pharmacol 153(4):684–692
195. 2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ Res 77(4):759–764
196. Kitamura K, Shibata R, Tsuji Y, Shimano M, Inden Y, Murohara T (2011) Eicosapentaenoic acid prevents atrial fibrillation associated with heart failure in a rabbit model. Am J Physiol Heart Circ Physiol 300(5):H1814–H1821
197. Klattenhoff CA, Scheuermann JC, Surface LE et al (2013) Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 152(3):570–583
198. Klein G, Schaefer A, Hilfiker-Kleiner D et al (2005) Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon. Circ Res 96(7):748–755
199. Kleinbongard P, Schulz R, Heusch G (2011) TNFalpha in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev 16(1):49–69
200. Koeth RA, Wang Z, Levison BS et al (2013) Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19(5):576–585
201. Kolwicz SC Jr, Purohit S, Tian R (2013) Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res 113(5):603–616
202. Kong Y, Tannous P, Lu G et al (2006) Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113(22):2579–2588
203. Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71(4):549–574
204. Konstantinidis K, Whelan RS, Kitsis RN (2012) Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol 32(7):1552–1562
205. Kook H, Lepore JJ, Gitler AD et al (2003) Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 112(6):863–871
206. Kranias EG, Hajjar RJ (2012) Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 110(12):1646–1660
207. Kreusser MM, Lehmann LH, Keranov S et al (2014) Cardiac CaM kinase II genes delta and gamma contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy. Circulation 130(15):1262–1273
208. Kubli DA, Gustafsson AB (2012) Mitochondria and mitophagy: the yin and yang of cell death control. Circ Res 111(9):1208–1221
209. Kubota T, McNamara DM, Wang JJ et al (1998) Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Circulation 97(25):2499–2501
210. Kumarswamy R, Thum T (2013) Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 113(6):676–689
211. Kumarswamy R, Bauters C, Volkmann I et al (2014) Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res 114(10):1569–1575
212. Kunisada K, Negoro S, Tone E et al (2000) Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 97(1):315–319
213. Ladage D, Tilemann L, Ishikawa K et al (2011) Inhibition of PKCalpha/beta with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury. Circ Res 109(12):1396–1400
214. Lahey R, Wang X, Carley AN, Lewandowski ED (2014) Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. Circulation 130(20):1790–1799
215. Lahm A, Paolini C, Pallaoro M et al (2007) Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 104(44):17335–17340
216. Lal H, Ahmad F, Woodgett J, Force T (2015) The GSK-3 family as therapeutic target for myocardial diseases. Circ Res 116(1):138–149
217. Landry J, Sutton A, Tafrov ST et al (2000) The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci USA 97(11):5807–5811
218. Langenickel TH, Dole WP (2012) Angiotensin receptor–neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today Ther Strateg 9(4):e131–e139
219. Laskowski A, Woodman OL, Cao AH et al (2006) Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72(1):112–123
220. Lee RC, Feinbaum RL, Ambros V (2004) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell S 116(2):843–854
221. Lee L, Campbell R, Scheuermann-Freestone M et al (2005) Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112(21):3280–3288
222. Lee SP, Kim HK, Kim YJ, Oh S, Sohn DW (2014) Association of myocardial angiogenesis with structural and functional ventricular remodeling in aortic stenosis patients with normal ejection fraction. J Cardiovasc Ultrasound 22(2):72–79
223. Lefkowitz RJ, Rockman HA, Koch WJ (2000) Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation 101(14):1634–1637
224. Lehmann LH, Worst BC, Stanmore DA, Backs J (2014) Histone deacetylase signaling in cardioprotection. Cell Mol Life Sci 71(9):1673–1690
225. Leopold JA (2011) Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation 124(18):e466–e468
226. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323(4):236–241
227. Levitan EB, Wolk A, Mittleman MA (2009) Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. Eur Heart J 30(12):1495–1500
228. Li HL, Yin R, Chen D et al (2007) Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J Cell Biochem 100(5):1086–1099
229. Liao R, Nascimben L, Friedrich J, Gwathmey JK, Ingwall JS (1996) Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ Res 78(5):893–902
230. Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ (1999) Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med 340(25):1933–1940
231. Liedtke AJ, DeMaison L, Nellis SH (1988) Effects of l-propionylcarnitine on mechanical recovery during reflow in intact hearts. Am J Physiol 255(1 Pt 2):H169–H176
232. Lijnen P, Petrov V (1999) Renin–angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol 31(5):949–970
233. Lin RCY, Weeks KL, Gao X-M et al (2010) PI3K (p110α) protects against myocardial infarction-induced heart failure/identification of PI3K-regulated miRNAs and mRNAs. Arterioscler Thromb Vasc Biol 30:724–732
234. Lin Z, Zhou P, von Gise A et al (2015) Pi3kcb links Hippo-YAP and PI3K–AKT signaling pathways to promote cardiomyocyte proliferation and survival. Circ Res 116(1):35–45
235. Lindner M, Brandt MC, Sauer H, Hescheler J, Bohle T, Beuckelmann DJ (2002) Calcium sparks in human ventricular cardiomyocytes from patients with terminal heart failure. Cell Calcium 31(4):175–182
236. Literati-Nagy B, Kulcsar E, Literati-Nagy Z et al (2009) Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: a proof of concept randomized double-blind clinical trial. Horm Metab Res 41(5):374–380
237. Literati-Nagy B, Peterfai E, Kulcsar E et al (2010) Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disorders. Brain Res Bull 83(6):340–344
238. Literati-Nagy Z, Tory K, Literati-Nagy B et al (2012) The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics. Cell Stress Chaperones 17(4):517–521
239. Liu Q, Molkentin JD (2011) Protein kinase Calpha as a heart failure therapeutic target. J Mol Cell Cardiol 51(4):474–478
240. Liu JC, Chan P, Chen JJ et al (2004) The inhibitory effect of trilinolein on norepinephrine-induced beta-myosin heavy chain promoter activity, reactive oxygen species generation, and extracellular signal-regulated kinase phosphorylation in neonatal rat cardiomyocytes. J Biomed Sci 11(1):11–18
241. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90(1):207–258
242. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ (2009) A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 15(1):75–83
243. Lou Q, Janardhan A, Efimov IR (2012) Remodeling of calcium handling in human heart failure. Adv Exp Med Biol 740:1145–1174
244. Lu J, McKinsey TA, Zhang CL, Olson EN (2000) Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell 6(2):233–244
245. Luczak ED, Anderson ME (2014) CaMKII oxidative activation and the pathogenesis of cardiac disease. J Mol Cell Cardiol 73:112–116
246. Luo J, McMullen JR, Sobkiw CL et al (2005) Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 25(21):9491–9502
247. Lydell CP, Chan A, Wambolt RB et al (2002) Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts. Cardiovasc Res 53(4):841–851
248. Ma Z, Qi J, Meng S, Wen B, Zhang J (2013) Swimming exercise training-induced left ventricular hypertrophy involves microRNAs and synergistic regulation of the PI3K/AKT/mTOR signaling pathway. Eur J Appl Physiol 113(10):2473–2486
249. Maejima Y, Chen Y, Isobe M, Gustafsson AB, Kitsis RN, Sadoshima J (2014) Recent progress in research on molecular mechanisms of autophagy in the heart. Am J Physiol Heart Circ Physiol. doi:10.1152/ajpheart.00711.2014:ajpheart00711
250. Mai W, Janier MF, Allioli N et al (2004) Thyroid hormone receptor alpha is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci USA 101(28):10332–10337
251. Makkar RR, Smith RR, Cheng K et al (2012) Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379(9819):895–904
252. Malliaras K, Makkar RR, Smith RR et al (2014) Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 63(2):110–122
253. Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91(11):988–998
254. Mann DL (2011) The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 108(9):1133–1145
255. Marber MS, Mestril R, Chi SH, Sayen MR, Yellon DM, Dillmann WH (1995) Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest 95(4):1446–1456
256. Marin-Garcia J, Goldenthal MJ, Moe GW (2001) Abnormal cardiac and skeletal muscle mitochondrial function in pacing-induced cardiac failure. Cardiovasc Res 52(1):103–110
257. Maron BA, Leopold JA (2010) Aldosterone receptor antagonists: effective but often forgotten. Circulation 121(7):934–939
258. Martelli AM, Zweyer M, Ochs RL et al (2001) Nuclear apoptotic changes: an overview. J Cell Biochem 82(4):634–646
259. Martin ML, Blaxall BC (2012) Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends? J Cardiovasc Transl Res 5(6):768–782
260. Martin ED, Bassi R, Marber MS (2014) p38 MAPK in cardioprotection—are we there yet? Br J Pharmacol. doi:10.1111/bph.12901
261. Marx SO, Reiken S, Hisamatsu Y et al (2000) PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101(4):365–376
262. Masumura Y, Kobayashi A, Yamazaki N (1990) Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. Jpn Circ J 54(12):1471–1476
263. Matkovich SJ (2014) MicroRNAs in the stressed heart: sorting the signal from the noise. Cells 3(3):778–801
264. McKinsey TA (2011) Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J Mol Cell Cardiol 51(4):491–496
265. McKinsey TA, Zhang CL, Lu J, Olson EN (2000a) Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408(6808):106–111
266. McKinsey TA, Zhang CL, Olson EN (2000b) Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA 97(26):14400–14405
267. McKinsey TA, Zhang CL, Olson EN (2002) Signaling chromatin to make muscle. Curr Opin Cell Biol 14(6):763–772
268. McLean BA, Zhabyeyev P, Pituskin E, Paterson I, Haykowsky MJ, Oudit GY (2013) PI3K inhibitors as novel cancer therapies: implications for cardiovascular medicine. J Card Fail 19(4):268–282
269. McMullen JR (2008) Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease. Clin Exp Pharmacol Physiol 35(3):349–354
270. McMullen JR, Shioi T, Zhang L et al (2003) Phosphoinositide 3-kinase (p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100(21):12355–12360
271. McMullen JR, Shioi T, Huang W-Y et al (2004) The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase (p110alpha) pathway. J Biol Chem 279(6):4782–4793
272. McMullen JR, Amirahmadi F, Woodcock EA et al (2007) Protective effects of exercise and phosphoinositide 3-kinase (p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 104(2):612–617
273. McMullen JR, Boey EJH, Ooi JYY, Seymour JF, Keating MJ, Tam CS (2014) Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K–Akt signaling. Blood 124(25):3829–3830
274. McMurray JJ (2010) Clinical practice. Systolic heart failure. N Engl J Med 362(3):228–238
275. McMurray JJV, Pfeffer MA (2005) Heart failure. Lancet 365:1877–1889
276. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ (1993) Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 14(11):1493–1498
277. McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004
278. Melling CW, Thorp DB, Milne KJ, Krause MP, Noble EG (2007) Exercise-mediated regulation of Hsp70 expression following aerobic exercise training. Am J Physiol Heart Circ Physiol 293(6):H3692–H3698
279. Menasche P, Alfieri O, Janssens S et al (2008) The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117(9):1189–1200
280. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ (1998) Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA 95(23):13893–13898
281. Mercer TR, Mattick JS (2013) Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 20(3):300–307
282. MERIT-HR Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169):2001–2007
283. Michalik KM, You X, Manavski Y et al (2014) Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 114(9):1389–1397
284. Miller TA, LeBrasseur NK, Cote GM et al (2005) Oleate prevents palmitate-induced cytotoxic stress in cardiac myocytes. Biochem Biophys Res Commun 336(1):309–315
285. Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12(5):341–355
286. Mingozzi F, High KA (2013) Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122(1):23–36
287. Miska EA, Karlsson C, Langley E, Nielsen SJ, Pines J, Kouzarides T (1999) HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J 18(18):5099–5107
288. Miyamoto MI, del Monte F, Schmidt U et al (2000) Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 97(2):793–798
289. Moc C, Taylor AE, Chesini GP et al (2015) Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophy. Cardiovasc Res 105(2):160–170
290. Modesti PA, Vanni S, Bertolozzi I et al (2000) Early sequence of cardiac adaptations and growth factor formation in pressure- and volume-overload hypertrophy. Am J Physiol Heart Circ Physiol 279(3):H976–H985
291. Molkentin JD, Lu J-R, Antos CL et al (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93(2):215–228
292. Montano MM, Desjardins CL, Doughman YQ et al (2013) Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse. Cardiovasc Res 99(1):74–82
293. Montgomery RL, Hullinger TG, Semus HM et al (2011) Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure/clinical perspective. Circulation 124(14):1537–1547
294. Morissette MR, Howes AL, Zhang T, Heller Brown J (2003) Upregulation of GLUT1 expression is necessary for hypertrophy and survival of neonatal rat cardiomyocytes. J Mol Cell Cardiol 35(10):1217–1227
295. Mortensen SA, Rosenfeldt F, Kumar A et al (2014) The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a Randomized Double-Blind Trial. JACC Heart Fail 2(6):641–649
296. Mourouzis I, Mantzouratou P, Galanopoulos G et al (2012) Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK signalings. Mol Cell Biochem 363(1–2):235–243
297. Mullard A (2014) New drugs cost US$2.6 billion to develop. Nat Rev Drug Discov 13(12):877
298. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM (1996) Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 77(9):723–727
299. Murdoch CE, Zhang M, Cave AC, Shah AM (2006) NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 71(2):208–215
300. Murry CE, Chong JJH, Laflamme MA (2014) Letter by Murry et al regarding article, “Embryonic stem cell-derived cardiac myocytes are not ready for human trials”. Circ Res 115(10):e28–e29
301. Naga Prasad SV, Esposito G, Mao L, Koch WJ, Rockman HA (2000) G-beta-gamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 275(7):4693–4698
302. Nagayama T, Hsu S, Zhang M et al (2009) Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53(2):207–215
303. Nakai A, Yamaguchi O, Takeda T et al (2007) The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 13(5):619–624
304. Nakamura Y, Ueshima H, Okamura T et al (2005) Association between fish consumption and all-cause and cause-specific mortality in Japan: NIPPON DATA80, 1980–99. Am J Med 118(3):239–245
305. Narula J, Haider N, Virmani R et al (1996) Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335(16):1182–1189
306. Neubauer S (2007) The failing heart—an engine out of fuel. N Engl J Med 356(11):1140–1151
307. Neubauer S, Horn M, Cramer M et al (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96(7):2190–2196
308. Nienaber JJ, Tachibana H, Naga Prasad SV et al (2003) Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Invest 112(7):1067–1079
309. Nishino Y, Miura T, Miki T et al (2004) Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res 61(3):610–619
310. Nordberg J, Arner ES (2001) Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31(11):1287–1312
311. O’Connell TD, Jensen BC, Baker AJ, Simpson PC (2014) Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev 66(1):308–333
312. Oka T, Akazawa H, Naito AT, Komuro I (2014) Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ Res 114(3):565–571
313. Okonko DO, Shah AM (2015) Heart failure: mitochondrial dysfunction and oxidative stress in CHF. Nat Rev Cardiol 12(1):6–8
314. Olivetti G, Abbi R, Quaini F et al (1997) Apoptosis in the failing human heart. N Engl J Med 336(16):1131–1141
315. Olson EN (2014) MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med 6(239):239ps3
316. Omori Y, Ohtani T, Sakata Y et al (2012) l-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 30(9):1834–1844
317. O’Neill BT, Kim J, Wende AR et al (2007) A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab 6(4):294–306
318. Ooi JYY, Bernardo BC, McMullen JR (2014) The therapeutic potential of microRNAs regulated in settings of physiological cardiac hypertrophy. Future Med Chem 6(2):205–222
319. Orom UA, Shiekhattar R (2013) Long noncoding RNAs usher in a new era in the biology of enhancers. Cell 154(6):1190–1193
320. O’Rourke B, Kass DA, Tomaselli GF, Kaab S, Tunin R, Marban E (1999) Mechanisms of altered excitation–contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ Res 84(5):562–570
321. Oudit GY, Kassiri Z (2007) Role of PI3 kinase gamma in excitation–contraction coupling and heart disease. Cardiovasc Hematol Disord: Drug Targets 7(4):295–304
322. Oudit GY, Crackower MA, Eriksson U et al (2003) Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108(17):2147–2152
323. Ounzain S, Micheletti R, Beckmann T et al (2015) Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. Eur Heart J 36(6):353–368
324. Packer M, Coats AJ, Fowler MB et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651–1658
325. Packer M, McMurray JJV, Desai AS et al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1):54–61
326. Palaniyandi SS, Sun L, Ferreira JCB, Mochly-Rosen D (2009) Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res 82(2):229–239
327. Pantos C, Mourouzis I, Galanopoulos G et al (2010) Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism. Horm Metab Res 42(10):718–724
328. Pantos C, Mourouzis I, Saranteas T et al (2011) Acute T3 treatment protects the heart against ischemia–reperfusion injury via TRalpha1 receptor. Mol Cell Biochem 353(1–2):235–241
329. Papoutsidakis N, Deftereos S, Kaoukis A et al (2013) MicroRNAs and the heart: small things do matter. Curr Top Med Chem 13(2):216–230
330. Pathak A, del Monte F, Zhao W et al (2005) Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96(7):756–766
331. Patrucco E, Notte A, Barberis L et al (2004) PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118(3):375–387
332. Paulin R, Sutendra G, Gurtu V et al (2015) A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension. Circ Res 116(1):56–69
333. Perrino C, Naga Prasad SV, Mao L et al (2006) Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest 116(6):1547–1560
334. Petretta M, Condorelli GL, Spinelli L et al (2000) Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am Heart J 140(6):E28
335. Pfeffer MA, Braunwald E, Moye LA et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327(10):669–677
336. Piccini JP, Whellan DJ, Berridge BR et al (2009) Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J 158(3):317–326
337. Piña IL, Apstein CS, Balady GJ et al (2003) Exercise and heart failure: a statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention. Circulation 107(8):1210–1225
338. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717
339. Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309–1321
340. Plumier JC, Ross BM, Currie RW et al (1995) Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery. J Clin Invest 95(4):1854–1860
341. Porrello ER, Mahmoud AI, Simpson E et al (2011) Transient regenerative potential of the neonatal mouse heart. Science 331(6020):1078–1080
342. Pretorius L, Du X-J, Woodcock EA et al (2009) Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol 175(3):998–1009
343. Qian J, Vafiadaki E, Florea SM et al (2011) Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling. Circ Res 108(12):1429–1438
344. Raake PW, Vinge LE, Gao E et al (2008) G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 103(4):413–422
345. Raake PW, Schlegel P, Ksienzyk J et al (2013) AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 34(19):1437–1447
346. Ravasi T, Suzuki H, Pang KC et al (2006) Experimental validation of the regulated expression of large numbers of non-coding RNAs from the mouse genome. Genome Res 16(1):11–19
347. Recchia FA, Bernstein RD, Sehgal PB, Ferreri NR, Hintze TH (2000) Cytokines are not a requisite part of the pathophysiology leading to cardiac decompensation. Proc Soc Exp Biol Med 223(1):47–52
348. Regitz V, Shug AL, Fleck E (1990) Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 65(11):755–760
349. Rengo G, Lymperopoulos A, Zincarelli C et al (2009) Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119(1):89–98
350. Rengo G, Cannavo A, Liccardo D et al (2013) Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis and remodeling in heart failure. Circ Heart Fail 6(6):1259–1267
351. Respress JL, Gershovich PM, Wang T et al (2014) Long-term simulated microgravity causes cardiac RyR2 phosphorylation and arrhythmias in mice. Int J Cardiol 176(3):994–1000
352. Ritchie RH, Love JE, Huynh K et al (2012) Enhanced phosphoinositide 3-kinase (p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 55(12):3369–3381
353. Rizos I (2000) Three-year survival of patients with heart failure caused by dilated cardiomyopathy and l-carnitine administration. Am Heart J 139(2 Pt 3):S120–S123
354. Rockman HA, Koch WJ, Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415(6868):206–212
355. Roman BB, Geenen DL, Leitges M, Buttrick PM (2001) PKC-beta is not necessary for cardiac hypertrophy. Am J Physiol Heart Circ Physiol 280(5):H2264–H2270
356. Rose BA, Force T, Wang Y (2010) Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 90(4):1507–1546
357. Rothermel BA, Hill JA (2008) Autophagy in load-induced heart disease. Circ Res 103(12):1363–1369
358. Ruppert C, Deiss K, Herrmann S et al (2013) Interference with ERKThr188 phosphorylation impairs pathological but not physiological cardiac hypertrophy. Proc Natl Acad Sci USA 110(18):7440–7445
359. Saddik M, Lopaschuk GD (1991) Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 266(13):8162–8170
360. Sadoshima J, Malhotra R, Izumo S (1996) The role of the cardiac renin–angiotensin system in load-induced cardiac hypertrophy. J Card Fail 2(4 Suppl):S1–S6
361. Sakamoto M, Minamino T, Toko H et al (2006) Upregulation of heat shock transcription factor 1 plays a critical role in adaptive cardiac hypertrophy. Circ Res 99(12):1411–1418
362. Samanen J (2013) Chapter 5—Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics. In: Ganellin R, Roberts S, Jefferis R (eds) Introduction to biological and small molecule drug research and development. Elsevier, Oxford, pp 161–203. doi:10.1016/B978-0-12-397176-0.00005-4
363. Sanganalmath SK, Bolli R (2013) Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 113(6):810–834
364. Sapra G, Tham YK, Cemerlang N et al (2014) The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. Nat Commun 5:5705
365. Sayed D, Abdellatif M (2011) MicroRNAs in development and disease. Physiol Rev 91(3):827–887
366. Schaper J, Meiser E, Stammler G (1985) Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. Circ Res 56(3):377–391
367. Schonekess BO, Allard MF, Lopaschuk GD (1995) Propionyl l-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 77(4):726–734
368. Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA (2012) Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 59(1):9–15
369. Schwarzer M, Osterholt M, Lunkenbein A, Schrepper A, Amorim P, Doenst T (2014) Mitochondrial reactive oxygen species production and respiratory complex activity in rats with pressure overload-induced heart failure. J Physiol 592(Pt 17):3767–3782
370. Schwinger RH, Munch G, Bolck B, Karczewski P, Krause EG, Erdmann E (1999) Reduced Ca(2 +)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 31(3):479–491
371. Schwingshackl L, Hoffmann G (2014) Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. Lipids Health Dis 13:154
372. Scimia MC, Cannavo A, Koch WJ (2013) Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium. Expert Rev Cardiovasc Ther 11(8):999–1013
373. Scimia MC, Gumpert AM, Koch WJ (2014) Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther 14(2):183–195
374. Serati AR, Motamedi MR, Emami S, Varedi P, Movahed MR (2010) l-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. Cardiology 116(3):178–182
375. Serneri GG, Modesti PA, Boddi M et al (1999) Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res 85(1):57–67
376. Shah AS, White DC, Emani S et al (2001) In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 103(9):1311–1316
377. Sheetz MJ, Aiello LP, Shahri N et al (2011) Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina 31(6):1053–1059
378. Shi J, Wei L (2012) Regulation of JAK/STAT signalling by SOCS in the myocardium. Cardiovasc Res 96(3):345–347
379. Shibata R, Ouchi N, Ito M et al (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10(12):1384–1389
380. Shioi T, Kang PM, Douglas PS et al (2000) The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19(11):2537–2548
381. Shiojima I, Sato K, Izumiya Y et al (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115(8):2108–2118
382. Siliprandi N, Di Lisa F, Menabo R (1991) Propionyl-l-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 5(Suppl 1):11–15
383. Small EM, Frost RJA, Olson EN (2010) MicroRNAs add a new dimension to cardiovascular disease. Circulation 121(8):1022–1032
384. Solaro RJ (2010) Sarcomere control mechanisms and the dynamics of the cardiac cycle. J Biomed Biotechnol 2010:105648
385. SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325(5):293–302
386. SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327(10):685–691
387. Song M, Chen Y, Gong G, Murphy E, Rabinovitch PS, Dorn GW 2nd (2014) Super-suppression of mitochondrial reactive oxygen species signaling impairs compensatory autophagy in primary mitophagic cardiomyopathy. Circ Res 115(3):348–353
388. Soonpaa MH, Field LJ (1998) Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res 83(1):15–26
389. Sorokina N, O’Donnell JM, McKinney RD et al (2007) Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 115(15):2033–2041
390. Stanley WC, Chandler MP (2002) Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 7(2):115–130
391. Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85(3):1093–1129
392. Suckau L, Fechner H, Chemaly E et al (2009) Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119(9):1241–1252
393. Sussman MA, Puceat M (2014) Response to letter regarding article, “Embryonic stem cell-derived cardiac myocytes are not ready for human trials”. Circ Res 115(10):e30–e31
394. Sussman MA, Lim HW, Gude N et al (1998) Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281(5383):1690–1693
395. Suzuki Y, Kamikawa T, Yamazaki N (1981) Effect of l-carnitine on cardiac hemodynamics. Jpn Heart J 22(2):219–225
396. Sweitzer NK (2003) What is an angiotensin converting enzyme inhibitor? Circulation 108(3):e16–e18
397. Taegtmeyer H (2002) Switching metabolic genes to build a better heart. Circulation 106(16):2043–2045
398. Taha M, Lopaschuk GD (2007) Alterations in energy metabolism in cardiomyopathies. Ann Med 39(8):594–607
399. Takahashi T, Allen PD, Izumo S (1992) Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2 +)-ATPase gene. Circ Res 71(1):9–17
400. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA (2000) Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res 86(12):1218–1223
401. Takimoto E, Kass DA (2007) Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49(2):241–248
402. Takimoto E, Champion HC, Li M et al (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11(2):214–222
403. Tannous P, Zhu H, Nemchenko A et al (2008) Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation 117(24):3070–3078
404. ter Maaten JM, Valente MAE, Damman K, Hillege HL, Navis G (2015) Diuretic response in acute heart failure—pathophysiology, evaluation, and therapy. Nat Rev Cardiol. doi:10.1038/nrcardio.2014.215
405. Thum T (2014) Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol 11(11):655–663
406. Thum T, Galuppo P, Wolf C et al (2007) MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116(3):258–267
407. Tian R, Nascimben L, Ingwall JS, Lorell BH (1997) Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 96(4):1313–1319
408. Tian R, Musi N, D’Agostino J, Hirshman MF, Goodyear LJ (2001) Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104(14):1664–1669
409. Tilemann L, Lee A, Ishikawa K et al (2013) SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med 5(211):211ra159
410. Torre-Amione G, Kapadia S, Lee J et al (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93(4):704–711
411. Urpi-Sarda M, Casas R, Chiva-Blanch G et al (2012) The Mediterranean diet pattern and its main components are associated with lower plasma concentrations of tumor necrosis factor receptor 60 in patients at high risk for cardiovascular disease. J Nutr 142(6):1019–1025
412. Ussher JR, Lopaschuk GD, Arduini A (2013) Gut microbiota metabolism of l-carnitine and cardiovascular risk. Atherosclerosis 231(2):456–461
413. Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J (2013) The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 10(2):85–97
414. van Berlo JH, Molkentin JD (2014) An emerging consensus on cardiac regeneration. Nat Med 20(12):1386–1393
415. van Berlo JH, Maillet M, Molkentin JD (2013) Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 123(1):37–45
416. van Bilsen M, Planavila A (2014) Fatty acids and cardiac disease: fuel carrying a message. Acta Physiol 211(3):476–490
417. van Rooij E, Sutherland LB, Liu N et al (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103(48):18255–18260
418. van Rooij E, Sutherland LB, Qi XX, Richardson JA, Hill J, Olson EN (2007) Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316(5824):575–579
419. van Rooij E, Purcell AL, Levin AA (2012) Developing microRNA therapeutics. Circ Res 110(3):496–507
420. Vandeput F, Krall J, Ockaili R et al (2009) cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 330(3):884–891
421. Vanderheyden M, Paulus WJ, Voss M et al (2005) Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. Heart 91(7):926–931
422. Vausort M, Wagner DR, Devaux Y (2014) Long noncoding RNAs in patients with acute myocardial infarction. Circ Res 115(7):668–677
423. Vega RB, Harrison BC, Meadows E et al (2004) Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24(19):8374–8385
424. Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP (2009) Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 120(23):2315–2321
425. Volkers M, Toko H, Doroudgar S et al (2013) Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1. Proc Natl Acad Sci USA 110(31):12661–12666
426. Wahlquist C, Jeong D, Rojas-Munoz A et al (2014) Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508:531–535
427. Wakasaki H, Koya D, Schoen FJ et al (1997) Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 94(17):9320–9325
428. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 283(5407):1482–1488
429. Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39:359–407
430. Walsh K, Shiojima I (2007) Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest 117(11):3176–3179
431. Wang EY, Biala AK, Gordon JW, Kirshenbaum LA (2012) Autophagy in the heart: too much of a good thing? J Cardiovasc Pharmacol 60(2):110–117
432. Wang K, Liu F, Zhou LY et al (2014) The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 114(9):1377–1388
433. Weeks KL, Avkiran M (2014) Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms. J Physiol. doi:10.1113/jphysiol.2014.282442
434. Weeks KL, Gao X, Du XJ et al (2012) Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail 5(4):523–534
435. Wei JQ, Shehadeh LA, Mitrani JM et al (2008) Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation 118(9):934–946
436. Wencker D, Chandra M, Nguyen K et al (2003) A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111(10):1497–1504
437. Westenbrink BD, Ling H, Miyamoto S et al (2015) Mitochondrial reprogramming induced by CaMKIIdelta mediates hypertrophy decompensation. Circ Res. doi:10.1161/CIRCRESAHA.116.304682
438. Wettschureck N, Rutten H, Zywietz A et al (2001) Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7(11):1236–1240
439. White FC, Bloor CM, McKirnan MD, Carroll SM (1998) Exercise training in swine promotes growth of arteriolar bed and capillary angiogenesis in heart. J Appl Physiol 85(3):1160–1168
440. White DC, Hata JA, Shah AS, Glower DD, Lefkowitz RJ, Koch WJ (2000) Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci USA 97(10):5428–5433
441. Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75(5):855–862
442. Willett WC (2006) Trans fatty acids and cardiovascular disease-epidemiological data. Atheroscler Suppl 7(2):5–8
443. Williams SM, Golden-Mason L, Ferguson BS et al (2014) Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 67:112–125
444. Wisloff U, Stoylen A, Loennechen JP et al (2007) Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 115(24):3086–3094
445. Wong MY, Yu Y, Walsh WR, Yang JL (2011) microRNA-34 family and treatment of cancers with mutant or wild-type p53 (review). Int J Oncol 38(5):1189–1195
446. Woodall MC, Ciccarelli M, Woodall BP, Koch WJ (2014) G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism. Circ Res 114(10):1661–1670
447. Wu G, Toyokawa T, Hahn H, Dorn GW 2nd (2000) Epsilon protein kinase C in pathological myocardial hypertrophy. Analysis by combined transgenic expression of translocation modifiers and Galphaq. J Biol Chem 275(39):29927–29930
448. 2+ signaling in cardiac myocyte excitation–transcription coupling. J Clin Invest 116(3):675–682
449. Xiang Y, Kobilka BK (2003) Myocyte adrenoceptor signaling pathways. Science 300(5625):1530–1532
450. Xie M, Hill JA (2013) HDAC-dependent ventricular remodeling. Trends Cardiovasc Med 23(6):229–235
451. Xie M, Kong Y, Tan W et al (2014) Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation 129(10):1139–1151
452. Xiong Q, Ye L, Zhang P et al (2013) Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling. Circulation 127(9):997–1008
453. Xu X, Lu Z, Fassett J et al (2014) Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase alpha2. Hypertension 63(4):723–728
454. Yamazaki T, Komuro I, Yazaki Y (1999) Role of the renin–angiotensin system in cardiac hypertrophy. Am J Cardiol 83(12A):53H–57H
455. Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128(16):1810–1852
456. Yang KC, Jay PY, McMullen JR, Nerbonne JM (2012) Enhanced cardiac PI3Kalpha signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure. Cardiovasc Res 93(2):252–262
457. Yang K-C, Yamada KA, Patel AY et al (2014) Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation 129(9):1009–1021
458. Yeh ETH, Tong AT, Lenihan DJ et al (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109(25):3122–3131
459. Yeh YH, Wakili R, Qi XY et al (2008) Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 1(2):93–102
460. Young MJ (2013) Targeting the mineralocorticoid receptor in cardiovascular disease. Expert Opin Ther Targets 17(3):321–331
461. Zaglia T, Milan G, Ruhs A et al (2014) Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy. J Clin Invest 124(6):2410–2424
462. Zangi L, Lui KO, von Gise A et al (2013) Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 31(10):898–907
463. Zangrando J, Zhang L, Vausort M et al (2014) Identification of candidate long non-coding RNAs in response to myocardial infarction. BMC Genom 15:460
464. Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21
465. Zarrinpashneh E, Beauloye C, Ginion A et al (2008) AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol. Biochem Biophys Res Commun 376(4):677–681
466. Zhabyeyev P, McLean B, Patel VB, Wang W, Ramprasath T, Oudit GY (2014) Dual loss of PI3Kalpha and PI3Kgamma signaling leads to an age-dependent cardiomyopathy. J Mol Cell Cardiol 77C:155–159
467. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002a) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110(4):479–488
468. Zhang CL, McKinsey TA, Olson EN (2002b) Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol 22(20):7302–7312
469. Zhang T, Maier LS, Dalton ND et al (2003) The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 92(8):912–919
470. Zhang P, Hu X, Xu X et al (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52(5):918–924
471. Zhu YC, Zhu YZ, Gohlke P, Stauss HM, Unger T (1997) Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am J Cardiol 80(3):110A–117A
472. Zsebo K, Yaroshinsky A, Rudy JJ et al (2014) Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 114(1):101–108